Purpose Foretinib can be an dental multikinase inhibitor targeting MET, VEGF, RON, AXL, and Tie up-2 receptors. dosing cohort. ORR by Response Evaluation Requirements in Solid Tumors (RECIST) 1.0 was 13.5%, median progression-free survival was 9.three months, and median overall survival had not been reached. The current presence of a germline mutation was extremely predictive… Continue reading Purpose Foretinib can be an dental multikinase inhibitor targeting MET, VEGF,